Revolutionizing Liver and Cardio-Metabolic Disease Treatment: 89bio Secures $250M in Funding

89bio, a pioneering clinical-stage biopharmaceutical company based in San Francisco, has successfully raised a substantial $250 million in its latest funding round. This significant investment underscores the confidence investors have in the company’s commitment to developing innovative therapies for liver and cardio-metabolic diseases. At the forefront of their pipeline is BIO89-100, a glycoPEGylated analog of FGF21, specifically engineered to tackle serious health issues, including nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent promising results from the Phase 1b/2a trials indicate that BIO89-100 is not only safe and well-tolerated, but also effective in significantly reducing liver fat and improving lipid profiles in patients suffering from NASH. With this new funding, 89bio aims to accelerate the development of BIO89-100, further driving its ongoing Phase 2 trial for SHTG. The capital raised will also support the expansion of their research and development initiatives, reinforcing their mission to put patients first while adhering to the highest standards of integrity and ethical practices. Headquartered in San Francisco with operations in Herzliya, Israel, 89bio is dedicated to fostering a culture of collaboration and innovation, working tirelessly to bring forward therapeutic solutions that improve the lives of those affected by complex liver and metabolic diseases. This funding marks a pivotal step in their journey towards transforming the landscape of treatment options for these critical health concerns.